Results 151 to 160 of about 3,726 (180)

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults

Expert Review of Clinical Immunology, 2021
Wolf-Henning Boehncke, Nicolò Costantino Brembilla, Michael J Nissen   +2 more
exaly  

Guselkumab (Tremfya) for Ulcerative Colitis

The Medical Letter on Drugs and Therapeutics
The interleukin (IL)-23 antagonist guselkumab (Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of
openaire   +2 more sources

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Lancet, The, 2020
Philip J Mease, Proton Rahman, Alice B Gottlieb   +2 more
exaly  

Real‐life experience of guselkumab in patients with psoriasis

Dermatologic Therapy, 2020
Igor Snast, Roie Holzman, Emmilia Hodak   +2 more
exaly  

Axonal sensorimotor polyneuropathy after starting guselkumab

Journal of Dermatological Treatment, 2022
Muzamil Chisti
exaly  

Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab

Journal of Cutaneous Medicine and Surgery, 2020
Khalad Maliyar, Melinda Gooderham
exaly  

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

Journal of Dermatological Treatment, 2022
Matteo Megna, Gabriella Fabbrocini, Eleonora Cinelli   +2 more
exaly  

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology, 2017
KRISTIAN Reich, , Peter Foley
exaly  

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Lancet, The, 2018
Atul Deodhar, Wolf-Henning Boehncke, Yanli Zhuang   +2 more
exaly  

Etanercept/guselkumab

Reactions Weekly, 2023
openaire   +1 more source